Treatment Satisfaction Under Rivaroxaban (ACTS/TSQM)

Trial Profile

Treatment Satisfaction Under Rivaroxaban (ACTS/TSQM)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Embolism; Stroke; Venous thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 14 Jun 2016 Status changed from recruiting to active, no longer recruiting.
    • 16 May 2016 Planned End Date changed from 1 May 2016 to 1 Jan 2020.
    • 11 Apr 2016 Planned End Date changed from 1 Jan 2020 to 1 May 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top